Brokerages Set MBX Biosciences, Inc. (NASDAQ:MBX) Target Price at $50.20

MBX Biosciences, Inc. (NASDAQ:MBX) has earned a consensus rating of “Moderate Buy” from the thirteen ratings firms that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell recommendation and eleven have assigned a buy recommendation to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $50.20.

MBX has been the topic of a number of recent analyst reports. Barclays assumed coverage on shares of MBX Biosciences in a report on Tuesday, January 27th. They issued an “overweight” rating and a $66.00 price objective on the stock. Guggenheim boosted their price target on MBX Biosciences from $77.00 to $88.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Stifel Nicolaus raised their price objective on MBX Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Friday, December 19th. TD Cowen initiated coverage on MBX Biosciences in a report on Tuesday, November 4th. They set a “buy” rating on the stock. Finally, UBS Group initiated coverage on MBX Biosciences in a research note on Wednesday, January 7th. They set a “buy” rating and a $60.00 target price for the company.

MBX Biosciences Stock Performance

NASDAQ MBX opened at $37.67 on Wednesday. MBX Biosciences has a fifty-two week low of $4.81 and a fifty-two week high of $44.89. The business has a 50 day moving average of $33.97. The stock has a market cap of $1.69 billion, a PE ratio of -15.76 and a beta of 0.87.

MBX Biosciences (NASDAQ:MBX) last posted its earnings results on Thursday, November 6th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.10.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. ProShare Advisors LLC acquired a new stake in shares of MBX Biosciences in the 4th quarter valued at about $227,000. UBS Group AG increased its holdings in MBX Biosciences by 363.1% in the fourth quarter. UBS Group AG now owns 281,212 shares of the company’s stock valued at $8,869,000 after buying an additional 220,487 shares during the last quarter. Vanguard Group Inc. raised its stake in MBX Biosciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 1,817,811 shares of the company’s stock valued at $57,334,000 after buying an additional 140,449 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in MBX Biosciences by 206.3% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 15,317 shares of the company’s stock worth $483,000 after buying an additional 10,317 shares during the last quarter. Finally, GF Fund Management CO. LTD. acquired a new position in shares of MBX Biosciences in the 4th quarter worth approximately $28,000.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.